We study bacterial colonization of the intestinal tract, to understand how both benign and pathological bacteria affect their environment. Our long-term goal is to treat intestinal diseases by genetically engineering bacteria in vivo.
The Ank Nijhawan research team is focused on improving outcomes for people living with or at risk for HIV, and ensuring their access to comprehensive healthcare and social support services. We also focus on individuals involved in the criminal legal system, and specifically the overlap of infectious diseases such as HIV, hepatitis, sexually transmitted infections and substance use.
The Oh lab is committed to elucidating how G protein-coupled Receptor (GPCR) works in regulating metabolism and identifying new avenues for developing therapeutics to treat metabolic syndromes such as type 2 diabetes, insulin resistance.
Our laboratory has a particular interest in hepatic metabolism and its regulation by the immune system. We utilize genetic, epigenetic and proteomic approaches, combined with detailed physiological studies, to understand the complex mechanisms that causally link inflammation to metabolic dysfunction in obesity and fatty liver disease.
Translational biophotonics for noninvasive detection of systemic disease.
The goal of our research is to identify key immune checkpoints of gastrointestinal disorders that could be targeted for therapeutic intervention and drug development.
Leveraging cutting-edge genetic and chemical screens to uncover novel and enhanced therapeutics for cancer treatment.
The global focus of the Pulmonary Physiology Laboratory is the study of pulmonary exercise physiology, particularly as it pertains to pulmonary disease, normal aging, obesity, ventilatory control during exercise, applied respiratory physiology, and clinical cardiopulmonary exercise testing. The Lab consists of three separate investigative laboratories: the pulmonary function laboratory, the cardiopulmonary exercise physiology laboratory, and the body composition laboratory including DEXA imaging for the determination of percent body fat, lean body mass, bone content, visceral fat, overall fat distribution, and their effects on breathing.
We are broadly interested in how energy is regulated on a systems level during infection. Our current projects are focused on understanding the role that adipose tissue plays in the response to influenza and SARS-CoV2.
The Reddy Lab focuses on restoring effective antigen presentation to enhance anti-tumor immunity in breast cancers.
The Reinecker laboratory unravels and targets molecular mechanisms of key human genetic variants that cause chronic inflammatory diseases and cancer by creating novel genetic mouse and human organotypic model systems.
The Rohatgi Lab focuses on the role of reverse cholesterol transport in atheroprotection.
Research in the Rothermel Laboratory focuses on deciphering the molecular mechanisms that control cardiac structure and function during normal development and in response to pathological stress.
Satterthwaite Lab studies the signals that control B lymphocyte development, activation, and differentiation into antibody-secreting plasma cells, both normally and in autoimmune diseases such as lupus. We hope that by defining these events, we can reveal new approaches to modulate antibody responses therapeutically.
The Saxena lab's research interests include Icodextin in high peritoneal transporters; Kremezin study in patients with chronic kidney disease; SV40 in focal segmental glomerulosclerosis; molecular studies in lupus nephritis.
The main focus in our laboratory is the identification and physiological characterization of adipocyte-specific gene products and the elucidation of pathways that are an integral part of the complex set of reactions that drive adipogenesis.
The ultimate aim of the Shiloh Lab is to contribute to the development of vaccines and treatments for Mycobacterium tuberculosis (Mtb).
In the Suleiman lab, we focus on studying the podocyte biology, specifically the actin dynamics and cytoskeleton. Our research includes examining the balance of Rac and RhoA, two members of the Rho small GTPases, in both healthy and diseased kidneys.
The Tatara Laboratory applies engineering technologies to study and treat infectious diseases. We are particularly engaged in device-related infection, orthopedic immunology, and pathogen virulence on biomaterial surfaces.
The Terada Lab is focused on several areas of cellular signaling which control basic mechanical and cell fate decision programs.
The Thinwa lab studies neurotropic viruses, host defense pathways, autophagy and brain development.
The Tong lab studies the cellular and molecular mechanisms of cardiovascular diseases associated with systemic metabolic disorders, particularly heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF), with an eye toward translating these findings into innovative solutions to clinical problems.
My research interests include prevention of progression of renal diseases, diagnoses, and management of lipid disorders in renal disease, hypertensive nephrosclerosis, the role of angiotensin II converting enzyme inhibitors, and angiotensin II receptor blockers in renal disease.
The Turer Lab is interested in finding genes with novel functions in intestinal immune homeostasis. Our projects generally involve a mix of experimental approaches examining both the intestinal epithelium as well as hematopoietic causes of intestinal inflammation.
